Overestimation of Amphotericin B Resistance in Candida auris with Sensititre YeastOne Antifungal Susceptibility Testing: a Need for Adjustment for Correct Interpretation.

Candida auris Sensititre YeastOne amphotericin B antifungal susceptibility testing epidemiological cutoff value resistance wild type upper limit value

Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
15 06 2023
Historique:
medline: 19 6 2023
pubmed: 11 4 2023
entrez: 10 4 2023
Statut: ppublish

Résumé

Significant variation in minimal inhibitory concentrations (MIC) has been reported for amphotericin B (AMB) and C. auris, depending on the antifungal susceptibility testing (AFST) method. Although the Sensititre YeastOne (SYO) is widely used in routine laboratory testing, data regarding its performance for the AFST of C. auris are scarce. We tested AMB against 65 C. auris clinical isolates with the SYO and the reference methodology by the Clinical and Laboratory Standards Institute (CLSI). The essential agreement (EA, ±1 dilution) between the two methods and the categorical agreement (CA) based on the Centers for Disease Control and Prevention (CDC)'s tentative breakpoint of MIC ≥ 2 mg/L were determined. The SYO wild type upper limit value (WT-UL) was determined using the ECOFFinder. The modal (range) CLSI growth inhibitory MIC was lower than the SYO colorimetric MIC [1(0.25-1) versus 2(1-8) mg/L, respectively]). The CLSI-colorimetric SYO EA was 29% and the CA was 11% (89% major errors; MaE). MaE were reduced when the SYO WT-UL of 8 mg/L was used (0% MaE). Alternatively, the use of SYO growth inhibition endpoints of MIC-1 (75% growth inhibition) or MIC-2 (50% growth inhibition) resulted in 88% CA with 12% MaE and 97% CA with 3% MaE, respectively. In conclusion, SYO overestimated AMB resistance in C. auris isolates when colorimetric MICs, as per SYO instructions and the CDC breakpoint of 2 mg/L, were used. This can be improved either by using the method-specific WT-UL MIC of 8 mg/L for colorimetric MICs or by determining growth inhibition MIC endpoints, regardless of the color.

Identifiants

pubmed: 37036351
doi: 10.1128/spectrum.04431-22
pmc: PMC10269614
doi:

Substances chimiques

Antifungal Agents 0
Amphotericin B 7XU7A7DROE

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0443122

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Antimicrob Agents Chemother. 2017 May 24;61(6):
pubmed: 28416539
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0051721
pubmed: 34228535
J Clin Microbiol. 2012 Dec;50(12):3921-6
pubmed: 23015676
Microbiol Spectr. 2022 Feb 23;10(1):e0171721
pubmed: 35196811
J Fungi (Basel). 2022 Mar 06;8(3):
pubmed: 35330269
Open Forum Infect Dis. 2019 Jun 01;6(7):ofz262
pubmed: 31281859
mBio. 2020 Jan 7;11(1):
pubmed: 31911492
Clin Infect Dis. 2016 Feb 15;62(4):e1-50
pubmed: 26679628
Antimicrob Agents Chemother. 2015 Nov;59(11):6725-32
pubmed: 26282428
Infect Dis Clin North Am. 2021 Jun;35(2):313-339
pubmed: 34016280
Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0224221
pubmed: 35007140
Clin Microbiol Infect. 2022 Jun;28(6):838-843
pubmed: 34915074
Mycoses. 2022 Mar;65(3):331-343
pubmed: 34953089
Indian J Med Microbiol. 2021 Apr;39(2):228-230
pubmed: 33785243
Antimicrob Agents Chemother. 2018 Dec 21;63(1):
pubmed: 30323038
Clin Infect Dis. 2017 Jan 15;64(2):134-140
pubmed: 27988485
Emerg Microbes Infect. 2018 Mar 29;7(1):43
pubmed: 29593275
MMWR Morb Mortal Wkly Rep. 2020 Jan 10;69(1):6-9
pubmed: 31917780
J Antimicrob Chemother. 2018 Apr 1;73(4):891-899
pubmed: 29325167
BMC Infect Dis. 2020 Nov 11;20(1):827
pubmed: 33176724
Int J Antimicrob Agents. 2022 Apr;59(4):106558
pubmed: 35227828
Int J Antimicrob Agents. 2019 May;53(5):541-546
pubmed: 30769198
Front Microbiol. 2021 Oct 07;12:757835
pubmed: 34691009
Clin Infect Dis. 2019 Jan 1;68(1):15-21
pubmed: 29788045
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37
pubmed: 23137135

Auteurs

Maria Siopi (M)

Clinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Ilektra Peroukidou (I)

Clinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Maria-Ioanna Beredaki (MI)

Clinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Bram Spruijtenburg (B)

Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
Centre of Expertise in Mycology, Radboud University Medical Center/Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.

Theun de Groot (T)

Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
Centre of Expertise in Mycology, Radboud University Medical Center/Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.

Jacques F Meis (JF)

Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
Centre of Expertise in Mycology, Radboud University Medical Center/Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.

Georgia Vrioni (G)

Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Athanasios Tsakris (A)

Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Spyros Pournaras (S)

Clinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Joseph Meletiadis (J)

Clinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH